Verily and Samsung collaborate to integrate Galaxy Watch data into clinical research and real-world evidence generation

Verily Life Sciences and Samsung Electronics America have announced a partnership to integrate data from the Galaxy Watch into Verily’s Pre precision health platform, supporting real-world research and evidence generation for life sciences and government organizations.

Announced at 2026 Healthcare Information and Management Systems Society (HIMSS) conference, the initiative will combine Samsung’s Galaxy Watch 8 with Verily’s Pre platform to enable the collection and analysis of longitudinal health data for research. Sensor data captured by the Galaxy Watch will be integrated into Verily’s Viewpoint Evidence solution, which operates on the Pre platform. The system allows research sponsors to conduct studies using re-contactable participant cohorts, enabling the collection of continuous health information alongside other data sources. According to the companies, the combined solution is intended to support real-world studies across a range of research settings.

Sponsors will be able to use Verily’s broader data infrastructure to manage and analyze these datasets, including the Refinery system for data harmonization and the Workbench environment for analysis, modeling, and activation. Verily will also provide AI- and machine learning–based analytics, along with expertise in digital measures and clinical trial support across regulatory, development, operational, and compliance activities.

Samsung’s Galaxy Watch has been verified for several health-related measurements, including heart rate, blood oxygen levels, and body composition. The device has also received clearance from the US Food and Drug Administration (FDA) for certain features, including a moderate to severe obstructive sleep apnea assessment and irregular heart rhythm notification, supporting its potential use as a data source in research settings.

Tyler Gipson, Senior Vice President of MX B2B at Samsung Electronics America, said the collaboration reflects the growing role of consumer technologies in health research. He added that the partnership with Verily aims to accelerate the use of these data in clinical research, “providing sponsors with the real-world evidence they need to advance new treatments and improve patient care.”

The joint offering will also give sponsors access to a longitudinal dataset derived from Verily’s network of consented participants. These datasets combine wearable sensor data with electronic medical records, survey responses, and other third-party information, harmonized at the individual level to support detailed analyses of health outcomes.

Sponsors will be able to design and conduct studies using Verily’s registry populations, enabling exploration of relationships between physiological signals, behaviors, and health outcomes, including sleep patterns and activity levels. Verily will also recruit and engage Samsung Galaxy Watch users to participate in research studies, supporting consistent device use and improving data capture.

Scott Burke, Chief Technology Officer at Verily, noted that consumer-facing technologies may help make research participation more accessible while enabling the use of digital biomarkers:

“The use of consumer-friendly devices in clinical research makes it easier for participants to engage in studies, while enabling sponsors to use advanced biomarkers to generate high-quality data. This collaboration realizes our vision to integrate health research into everyday life, in order to generate better evidence and make precision health possible for all.”

The companies also indicated that they will explore the joint development of additional end-to-end solutions for clinical research as part of the collaboration.